当前位置:首页>产品中心>单抗/多抗>Anti-Human HTATSF1 Polyclonal Antibody|抗人HTATSF1多克隆抗体(靶标:人HIV Tat特异性因子1)

Anti-Human HTATSF1 Polyclonal Antibody|抗人HTATSF1多克隆抗体(靶标:人HIV Tat特异性因子1)

  • 货号:RB9THD661014
  • 价格:面议
  • 点击:219
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Mouse, Human
靶标17S U2 SnRNP complex component HTATSF1, HIV Tat-specific factor 1, HTATSF1, Tat-SF1
免疫原E. coli - derived recombinant Human HTATSF1 (Phe125-Ser389).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号O43719
背景信息

17S U2 SnRNP complex component HTATSF1 is a ~85 kDa protein. Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs. The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing. Within the 17S U2 SnRNP complex, HTATSF1 is required to stabilize the branchpoint-interacting stem loop. HTATSF1 is displaced from the 17S U2 SnRNP complex before the stable addition of the 17S U2 SnRNP complex to the spliceosome, destabilizing the branchpoint-interacting stem loop and allowing to probe intron branch site sequences. Also acts as a regulator of transcriptional elongation, possibly by mediating the reciprocal stimulatory effect of splicing on transcriptional elongation.

1. Loerch, S. et al. (2019) The Journal of biological chemistry 294, 2892-2902. PMID: 30567737
2. Zhang, Z. et al. (2020) Nature 583, 310-313. PMID: 32494006
3. Tholen, J. et al. (2022) Science (New York, N.Y.) 375, 50-57. PMID: 34822310
4. Kim, JB. et al. (1999) Molecular and cellular biology 19, 5960-8. PMID: 10454543
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 585
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 848
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 719
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 536
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 544
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 778
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 770
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 861
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 795
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 745
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 571
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 660
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 864
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 583
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 741
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 637
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 730
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 610
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 765
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 526
总计 33037 个记录,共 1652 页,当前第 1645 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30